Tempest Therapeutics, Inc..
TPST.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms. The company's lead program is TPST-1120, an oral selective PPARα antagonist, is being evaluated in clinical trials for hepatocellular...Show More
Better Health for All
-10
Tempest Therapeutics is a clinical-stage oncology company with its entire product pipeline dedicated to treating cancer and related conditions. Its lead candidate, amezalpat (TPST-1120), has shown promising Phase 1b/2 data for hepatocellular carcinoma (HCC), including a 6-month improvement in median overall survival and a 35% reduction in death risk compared to standard of care.
1
This product has received FDA Fast Track and Orphan Drug designations, and global regulatory approval to proceed with a pivotal Phase 3 trial.
2
Another candidate, TPST-1495, has FDA Orphan Drug designation for Familial Adenomatous Polyposis (FAP), a condition that often leads to colorectal cancer, and is in a Phase 2 trial.
3
As a clinical-stage company, it is not currently generating product revenue from harmful products.
4
The safety profile for TPST-1495 showed 30% of 27 subjects experienced a Grade 3 treatment-related adverse event (TRAE), with no Grade 4 or 5 AEs.
5
For TPST-1120, only one Grade 3 related adverse event was reported, and no >Grade 3 AEs.
6
The company's R&D expenses for the nine months ended September 30, 2025, were $12.1 million, down from $17.7 million in the same period in 2024, and Q3 2025 R&D expenses were $0.6 million, down from $7.6 million in Q3 2024.
7
The company also implemented a reduction in force in April 2025 to preserve capital.
8
The company's products target diseases with high unmet needs like HCC, which affects over 900,000 people worldwide annually and has the largest patient population in China, and FAP, which affects 1 in 5,000 to 10,000 US individuals.
9
The company adheres to GCP requirements and FDA regulations for clinical trials, including IRB review and public registry reporting.
10
The company's patent portfolio includes issued US patents for TPST-1120 expiring in December 2033 and TPST-1495 expiring in April 2039, with no evidence of specific patent flexibility initiatives.
11
Fair Money & Economic Opportunity
0
No evidence available to assess Tempest Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned across the provided articles.
1
While Nasdaq non-compliance letters were noted,
2
these are not labor-law breaches. Employee reviews mention concerns about low pay and lack of benefits, but no quantitative data on living wage coverage, health insurance coverage, or pay equity is available.
3
Information on layoffs is provided,
4
but this does not constitute voluntary turnover. No data is available for CEO to median pay ratio, collective bargaining share, safety incident rate, worker engagement score, or insecure contract share.
5
Fair Trade & Ethical Sourcing
0
No evidence available to assess Tempest Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No data was available from the provided article to assess Tempest Therapeutics, Inc. against the 'Honest & Fair Business' ethical value.
1
The request to access the SEC.gov article was throttled, resulting in no information for analysis.
2
Kind to Animals
0
The company conducts animal testing, as evidenced by the use of mice in preclinical data and in vivo studies for its lead program, TPST-1120.
1
However, the provided articles do not offer specific quantitative data on the volume of animals used, the company's animal testing policies, the extent of its use of non-animal testing methods, or any other animal welfare-related metrics required by the rubric.
No War, No Weapons
0
Tempest Therapeutics, Inc. is a clinical-stage oncology company focused on developing small molecule therapeutics.
1
The provided articles, including corporate governance guidelines, a code of business conduct, and financial reports, consistently indicate that the company's core business is in pharmaceuticals and cancer treatment. There is no evidence of involvement in arms manufacturing, military contracts, dual-use technologies with military applications, sales to embargoed regimes, peacebuilding investments, or any other activities directly related to the 'No War, No Weapons' ethical value.
2
Therefore, all KPIs are scored as N/A, reflecting no defense or arms-related activities in its core business or operations.
Planet-Friendly Business
0
No specific quantitative data is available to assess Tempest Therapeutics, Inc. against the Planet-Friendly Business KPIs.
1
The company's 2024 Sustainability Report announces alignment with updated European standards (ESRS) and details commitments to environmental respect, responsible water and energy management, material recovery, and emission control.
2
However, it does not provide numerical values for any relevant metrics.
3
Other sources explicitly state that sustainability data for the company is currently unavailable.
4
Respect for Cultures & Communities
0
No specific data points or factual evidence related to Tempest Therapeutics, Inc.'s performance on 'Respect for Cultures & Communities' were found in the provided articles. The articles either resulted in a 404 error or explicitly stated that no relevant data was present.
1
Safe & Smart Tech
0
Tempest Labs, Inc. is SOC 2 Type 1 Certified.
1
There are no documented incidents of unauthorized data use.
2
The company's privacy policy allows users to opt out of marketing emails and limit online tracking.
3
Data is retained as long as reasonably necessary for business needs or legal requirements.
4
The company's privacy policy states compliance with applicable laws, and management concluded that disclosure controls and procedures were effective as of March 31, 2025.
5
Zero Waste & Sustainable Products
10
Tempest Therapeutics has achieved 100% sustainable packaging, which is 100% plastic-free, fully compostable, recyclable, and biodegradable, utilizing Cruz Foam made from naturally derived materials.
1
This redesign has eliminated plastic from its packaging, representing a 100% reduction in single-use plastics in this area.
2
The company also offers a Recycling Program for its Tempest Weather Station, allowing customers to return old units for breakdown into core elements for recycling, indicating 100% product coverage for this specific product.
3
Tempest hardware is designed to last ten years or more, which is at the industry standard.
4
The company has implemented waste reduction initiatives through its packaging innovation, a partnership with Cruz Foam, and encouraging the repurposing of old tablets.
5
Cruz Foam, used in packaging, is made from upcycled food waste.
6
However, the company's circular design principles are generally stated as supporting a circular economy, with the packaging designed to return to the earth, but lacks broader integration across all product development.
7
There are no specific waste reduction or recyclability requirements for suppliers beyond Cruz Foam's material source.
8
Material efficiency is noted for the tablet stand made from renewable bamboo, but no comparative data to industry average is provided.
9